Blocklisting Application

15 August 2012

PuriCore plc

("PuriCore" or the "Company")

Blocklisting Application

PuriCore plc (LSE: PURI), the water-based clean technology company, announces that application has today been made to the UK Listing Authority for the blocklisting of, and to the London Stock Exchange for the admission of, 2,000,000 ordinary shares of 10p each to be admitted to the Official List. 

The block admission relates to ordinary shares that will be allotted from time to time in accordance with the exercise of options under the PuriCore Executive Omnibus Incentive Plan and will rank pari passu with the existing ordinary shares in issue. It is anticipated that admission will take place on 20 August 2012.

Enquiries:

UK

FTI Consulting

Susan Stuart

Victoria Foster Mitchell

+44 (0) 20 7831 3113

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. The Company's technologies are proven to be safe and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. The Company's products are the de facto standard for food safety in leading US supermarket chains. PuriCore also offers a breakthrough wound therapy solution to treat chronic and acute wounds including diabetic ulcers and burns.

PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.